CAJ | 학술논문

目的探讨在过敏性哮喘尘螨特异性免疫治疗(SIT)过程中转录因子Foxp3、IL-27 p28和EBI3 mRNA在外周血单个核细胞中表达的变化.方法根据进行抗原特异性免疫治疗的时间,采集过敏性哮喘患儿39例,分离其SIT治疗前、治疗一年后和治疗两年后的外周静脉血单个核细胞,提取总RNA,逆转录成cDNA,利用荧光定量PCR的方法检测Foxp3、IL-27 p28和EBI3 mRNA的表达情况,并观察患儿治疗前后的临床疗效.结果随着SIT治疗的进行,患儿临床症状明显减轻,与SIT治疗前相比,治疗一年和两年后,外周血中Foxp3的mRNA表达水平明显升高,分别为治疗前的5.03倍和1.93倍,差异有统计学意义(P=0.0008,P =0.033)；IL-27 EBI3的mRNA表达水平虽然有所升高,分别为治疗前的1.56倍和1.32倍,但差异并没有统计学意义(P =0.088,P=0.244);IL-27 p28的mRNA表达水平在治疗一年后明显升高,为治疗前的2.18倍,差异有统计学意义(P=0.027),治疗两年后又基本恢复至治疗前水平.结论哮喘患儿特异性免疫治疗有效；Foxp3转录因子和IL-27在哮喘的发生和SIT治疗中起重要作用.
목적 탐토재과민성효천진만특이성면역치료(SIT)과정중전록인자Foxp3、IL-27 p28화EBI3 mRNA재외주혈단개핵세포중표체적변화.방법 근거진행항원특이성면역치료적시간,채집과민성효천환인39례,분리기SIT치료전、치료일년후화치료량년후적외주정맥혈단개핵세포,제취총RNA,역전록성cDNA,이용형광정량PCR적방법검측Foxp3、IL-27 p28화EBI3 mRNA적표체정황,병관찰환인치료전후적림상료효.결과 수착SIT치료적진행,환인림상증상명현감경,여SIT치료전상비,치료일년화량년후,외주혈중Foxp3적mRNA표체수평명현승고,분별위치료전적5.03배화1.93배,차이유통계학의의(P=0.0008,P =0.033)；IL-27 EBI3적mRNA표체수평수연유소승고,분별위치료전적1.56배화1.32배,단차이병몰유통계학의의(P =0.088,P=0.244);IL-27 p28적mRNA표체수평재치료일년후명현승고,위치료전적2.18배,차이유통계학의의(P=0.027),치료량년후우기본회복지치료전수평.결론 효천환인특이성면역치료유효；Foxp3전록인자화IL-27재효천적발생화SIT치료중기중요작용.
Objective Objective To investigate the expression of Foxp3 transcription factor,Interleu kin-27 (IL-27) p28 and EBI3 in children with allergic asthma treated with specific immunotherapy (SIT).Methods According to the time of antigen-specific immunotherapy,the periphery venous blood of 39 children with allergic asthma were harvested at the time of one year before SIT,one year and two years after SIT respectively,then the peripheral blood mononuclear cells (PBMCs) were separated and total RNA was extracted and reverse transcribed into cDNA.The expression of Foxp3,IL-27p28 and EBI3 mRNA in PBMCs were detected by real-time PCR.Meanwhile,the clinical effects of the treatment were observed.Results According to the time of SIT treatment,the clinical symptom was significantly alleviated,Comparing to the expression before SIT treatment,1 or 2 years after SIT treatment,the expression of Foxp3 mRNA in peripheral blood was significantly increased to 5.03 times or 1.93 times the expression at pretreatment respectively (P =0.0008,P =0.033).The expression of IL-27 EBI3 mRNA was increased to 1.56 times and 1.32 times the pretreatment respectively (P =0.088,P =0.244).The expression of IL-27 p28 mRNA significantly increased to 2.18 times the pretreatment at 1 year after SIT treatment (P =0.027),but its expression returned to basic level as pretreatment at 2 years after of SIT treatment.Conclusions SIT is an effective therapy for the children with allergic asthma.Therefore,Foxp3 and IL-27 may play important roles in the pathogontosis of asthma.